HLA-B
HLA-B (HLA class I histocompatibility antigen, B alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Oesophageal cancer, Head and neck squamous cell carcinoma and 3 more.
Overview
Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumour-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells. May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.52 (direct and indirect evidence; datatypes literature 0.86, animal model 0.48, genetic association 0.00, somatic mutation 0.80). IntOGen calls it a driver in 6 cohorts (0 activating, 6 loss-of-function), covering Cervical Squamous Cell Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Oesophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · HLA-B (HLA class I histocompatibility antigen, B alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Oesophageal cancer, Head and neck squamous cell carcinoma and 3 more.
- 1 · What it is
HLA-B (HLA class I histocompatibility antigen, B alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Oesophageal cancer, Head and neck squamous cell carcinoma and 3 more.
- 2 · What goes wrong in cancer
Antigen-presenting major histocompatibility complex class I (MHCI) molecule.
- 3 · How drugs use it
No product in this corpus aims at HLA-B yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:4932 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P01889 (protein name, function text, keywords and locations (REST API)); CIViC gene HLA-B (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000234745 (association with cancer (MONDO_0004992) 0.52; (GraphQL API, CC0)); IntOGen HLA-B (driver in 6 cohorts (Act 0, LoF 6); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumour-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells. May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity. Both the peptide and the MHC molecule are recognised by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells. Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via constitutive proteasome and IFNG-induced immunoproteasome. Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9. Location: Cell membrane; Endoplasmic reticulum membrane (UniProt). Locus 6p21.33 (HGNC).
- Cervical cancer: IntOGen driver in 1 cohort (CESC)
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (MLYM)
- Diffuse large B-cell lymphoma: CIViC evidence names this disease; IntOGen driver in 2 cohorts (DLBCLNOS)
- Oesophageal and junctional adenocarcinoma: IntOGen driver in 1 cohort (ESCA)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 6 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"HLA-B" OR ABSTRACT:"HLA-B" OR TITLE:"major histocompatibility complex, class I, B" OR ABSTRACT:"major histocompatibility complex, class I, B" OR TITLE:"HLA class I histocompatibility antigen, B alpha chain" OR ABSTRACT:"HLA class I histocompatibility antigen, B alpha chain") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HLA-B, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetH3C2
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Non-Hodgkin lymphoma (all types), CIViC.
- TargetZNF750
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
- TargetCDX2
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, CIViC, IntOGen.
- TargetTGFBR1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
- TargetNBEA
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Cervical cancer, IntOGen.
- TargetCANT1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetZNF208
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetNUMA1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.